WAFAA FARAG: Open Payments
NPI 1205894920 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,595 in 46 payments from 11 companies in 2025. Trend: 2023 $665 · 2024 $1,015 · 2025 $1,595
Food & beverage: $1,595
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 6 | $317 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $309 |
| Indivior Inc. | 6 | $269 |
| ABBVIE INC. | 12 | $254 |
| Otsuka America Pharmaceutical, Inc. | 4 | $105 |
| Axsome Therapeutics, Inc. | 1 | $104 |
| Braeburn Inc. | 4 | $91 |
| Almatica Pharma LLC | 2 | $56 |
| Neurocrine BioSciences, Inc. | 2 | $45 |
| Lundbeck LLC | 1 | $25 |
Products named: CAPLYTA, SUBLOCADE, VRAYLAR, ARISTADA, LYBALVI, REXULTI, Auvelity, BRIXADI.
Industry payments across TX — which companies pay providers there.
